## Edgar Filing: Intra-Cellular Therapies, Inc. - Form 4

Intra-Cellular Therapies, Inc. Form 4 January 06, 2015

January 06, 2015											
FORM 4			CECU			CHANGE		NT.	APPROVAL		
	UNITED	STATES					COMMISSIO	N OMB Number:	3235-0287		
Check this box		Washington, D.C. 20549							January 31		
if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL OWNERSHI SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1 Section 17(a) of the Public Utility Holding Company Act of 1935 or 30(h) of the Investment Company Act of 1940							nge Act of 1934, of 1935 or Secti	Estimated average burden hours per response 0.5 4,			
(Print or Type Respon	ises)										
1. Name and Address of Reporting Person <u>*</u> Hineline Lawrence J.			2. Issuer Name <b>and</b> Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ITC]				<ul><li>5. Relationship of Reporting Person(s) to Issuer</li></ul>				
(Last) (First) (Middle)			3. Date of Earliest Transaction				(Ch	eck all applicab	le)		
C/O INTRA-CEI THERAPIES, IN BROADWAY			(Month/) 01/02/2	Day/Year) 2015			Director X Officer (gi below) VF		% Owner her (specify O		
	Street)			endment, D onth/Day/Yea	-	ป	6. Individual or Applicable Line) _X_ Form filed by Form filed by		Person		
NEW YORK, NY	¥ 10032						Person		epotting		
(City) (S	State)	(Zip)	Tab	ole I - Non-	Derivative	Securities A	cquired, Disposed	of, or Beneficia	ally Owned		
	nsaction Date th/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4)	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Report on	a separate line	for each cl	ass of sec	urities bene	ficially ow	ned directly o	or indirectly.				
	·				Perso inform requir	ons who res nation cont red to respo ays a curre	pond to the colle ained in this form ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)		
	Tabl	le II - Deriv	ative Sec	curities Acc	quired, Dis	posed of, or	Beneficially Owner	d			

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D

## Edgar Filing: Intra-Cellular Therapies, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)		red (A) posed of 3, 4,	(Month/Day,	(Year)	(Instr. 3 and	4)
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 17.57	01/02/2015		А	72,12	20	<u>(1)</u>	01/02/2025	Common Stock	72,120
Reporting Owners										
<b>Reporting Owner Name / Address</b>				Rel	ationshi	ps				
			Director	r 10% Ov	vner	Officer		Other		
Hineline Lawrence J. C/O INTRA-CELLULAR THERAPIES, INC. 3960 BROADWAY NEW YORK, NY 10032			S, INC.							
Signa	tures									
/s/ Lawre Hineline	ence J.	01/06/20	15							

\*\*Signature of Reporting Date Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests as to one third of the shares on January 2, 2016, one third of the shares on January 2, 2017 and one third of the shares on January 2, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (.